Novo Nordisk to Acquire Akero Therapeutics for $5.2 Billion, Secures Future Value with Efruxifermin
Novo Nordisk A/S (NYSE: NVO) announced today that it will acquire Akero Therapeutics (NASDAQ: AKRO) for...
Insight, China's Pharmaceutical Industry
Fineline Insights, Pharma Clarity